156 related articles for article (PubMed ID: 10331440)
1. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
[TBL] [Abstract][Full Text] [Related]
2. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
Lori F; Jessen H; Lieberman J; Finzi D; Rosenberg E; Tinelli C; Walker B; Siliciano RF; Lisziewicz J
J Infect Dis; 1999 Dec; 180(6):1827-32. PubMed ID: 10558937
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
[TBL] [Abstract][Full Text] [Related]
4. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea - new observations.
Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
[TBL] [Abstract][Full Text] [Related]
6. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
7. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
[TBL] [Abstract][Full Text] [Related]
8. Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.
Nokta M; Rossero R; Nichols J; Rosenbaum M; Pollard RB
AIDS Res Hum Retroviruses; 1999 Feb; 15(3):255-64. PubMed ID: 10052756
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lori F; Lisziewicz J
Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
[TBL] [Abstract][Full Text] [Related]
11. Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Landay AL; Bettendorf D; Chan E; Spritzler J; Schmitz JL; Bucy RP; Gonzalez CJ; Schnizlein-Bick CT; Evans T; Squires KE; Phair JP
AIDS Res Hum Retroviruses; 2002 Jan; 18(2):95-102. PubMed ID: 11839142
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
Lisziewicz J; Jessen H; Finzi D; Siliciano RF; Lori F
Lancet; 1998 Jul; 352(9123):199-200. PubMed ID: 9683211
[No Abstract] [Full Text] [Related]
13. [Hydroxyurea and HIV infection].
Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
[TBL] [Abstract][Full Text] [Related]
14. Frequency of cytokine-producing T cells in HIV-infected patients treated with stavudine, didanosine, and ritonavir.
Levacher M; Bouscarat F; Landman R; Chau F; Damond F; Gaudebout C; Mathez D; Leibowitch J; Saimot AG; Sinet M
AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1869-75. PubMed ID: 11118072
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Dybul M; Hidalgo B; Chun TW; Belson M; Migueles SA; Justement JS; Herpin B; Perry C; Hallahan CW; Davey RT; Metcalf JA; Connors M; Fauci AS
J Infect Dis; 2002 Jan; 185(1):61-8. PubMed ID: 11756982
[TBL] [Abstract][Full Text] [Related]
16. Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.
Benito JM; López M; Ballesteros C; Lozano S; Capa L; Barreiro P; Sempere J; Gonzalez-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):734-43. PubMed ID: 16910828
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy.
Amado RG; Jamieson BD; Cortado R; Cole SW; Zack JA
J Virol; 1999 Aug; 73(8):6361-9. PubMed ID: 10400728
[TBL] [Abstract][Full Text] [Related]
18. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
19. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea for HIV infection.
Zachary KC; Davis B
AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
